Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2NN
|
|||
| Former ID |
DNCL001762
|
|||
| Drug Name |
BIBT986
|
|||
| Synonyms |
Tanogitran; UNII-X5QRR6Z56Q; X5QRR6Z56Q; CHEMBL1270156; Tanogitran [INN]; BIBT986; 637328-69-9; SCHEMBL2471738; MAOALPSHCIBFJZ-RUZDIDTESA-N; ZINC64527030; BDBM50328705; J3.538.630K; (R)-2-(4-Amidinophenylaminomethyl)-1-methyl-5-[l -(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl]-benzimidazole; (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl) -ethyl]-benzimidazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H31N7O3
|
|||
| Canonical SMILES |
CC(C1=CC2=C(C=C1)N(C(=N2)CNC3=CC=C(C=C3)C(=N)N)C)(C(=O)N4CCCC4)NCC(=O)O
|
|||
| InChI |
1S/C25H31N7O3/c1-25(29-15-22(33)34,24(35)32-11-3-4-12-32)17-7-10-20-19(13-17)30-21(31(20)2)14-28-18-8-5-16(6-9-18)23(26)27/h5-10,13,28-29H,3-4,11-12,14-15H2,1-2H3,(H3,26,27)(H,33,34)/t25-/m1/s1
|
|||
| InChIKey |
MAOALPSHCIBFJZ-RUZDIDTESA-N
|
|||
| CAS Number |
CAS 637328-69-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor Xa (F10) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024917) | |||
| REF 2 | Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.